Rosiglitazone and Outcomes for Patients With Diabetes Mellitus and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial | Zendy

Richard G. Bach | Zendy; Maria M. Brooks | Zendy; M. Lombardero | Zendy; Saul Genuth | Zendy; Thomas Donner | Zendy; Alan J. Garber | Zendy; Laurence Kennedy | Zendy; E. Scott Monrad | Zendy; Rodica PopBusui | Zendy; Sheryl F. Kelsey | Zendy; Robert L. Frye | Zendy

Open Access

Rosiglitazone and Outcomes for Patients With Diabetes Mellitus and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial

Author(s) -

Richard G. Bach,

Maria M. Brooks,

M. Lombardero,

Saul Genuth,

Thomas Donner,

Alan J. Garber,

Laurence Kennedy,

E. Scott Monrad,

Rodica PopBusui,

Sheryl F. Kelsey,

Robert L. Frye

Publication year - 2013

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.112.000678

Subject(s) - medicine , rosiglitazone , myocardial infarction , cardiology , hazard ratio , diabetes mellitus , heart failure , coronary artery disease , stroke (engine) , angioplasty , surgery , confidence interval , insulin , endocrinology , mechanical engineering , engineering

Rosiglitazone improves glycemic control for patients with type 2 diabetes mellitus, but there remains controversy regarding an observed association with cardiovascular hazard. The cardiovascular effects of rosiglitazone for patients with coronary artery disease remain unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research